Developed Europe

Sterile Focus Brands are the leading contributor to the region. The region holds key manufacturing sites which form the base of our strategic growth plans. The API site at Oss, supported by its satellite operation at Sioux City, supplies APIs worldwide. The Notre Dame de Bondeville and Bad Oldesloe sites are strategically important manufacturers for the Group.

Key Countries

France,
Germany,
Italy,
The Netherlands,
United Kingdom

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Developed Europe pharmaceutical sector was valued at USD207 billion as at 31 December 2018
EU5* represent 77% of the value in Europe^ injectable Anaesthetics market with a 2 year CAGR of 7% p.a. in value

* EU5: France, Germany, Italy, Spain and the United Kingdom
^ IQVIA definition. Europe EU28 member states (including EU5) plus Switzerland.

Source: December 2018 IQVIA

STATISTICS

Number of products launched:

Nil

(2018: nil)

In-market sales value of pipeline as at 30 June 2019 anticipated to be launched in:

0 – 2 years

USD38 million

3 – 5 years

Nil

Number of product recalls:

4

(2018: 7)

Average staff turnover:

9,2%

(2018: 8,4%)

Number of work-related fatalities:

Nil

(2018: nil)

Number of permanent employees:

Revenue	2019 R’million	2018 (CER) R’million	change %
Total	12 329	13 022	(7)
Regional Brands	1 779	1 894	(6)
Sterile Focus Brands	5 602	5 935	(6)
Thrombosis Brands	2 191	2 267	(3)
Total Commercial Pharmaceuticals	3 411	3 668	(7)
Total Manufacturing revenue	7 381	7 829	(6)
Finished dose form	4 714	5 193	(9)
Active pharmaceutical ingredients	627	666	(6)
Total	4 087	4 527	(10)

Note: Commercial Pharmaceuticals revenue is disclosed by customer geography and manufacturing revenue by place of manufacture.